Additional research into the biological implications of m6A modifications in various human pathologies, such as obesity and cancer, are required to fully understand their roles in such diseases and to develop precise therapies such as FTO small-molecule inhibitors in conjunction with traditional therapies, for better outcomes. Here, FTO is linked to obesity due to melanocortin 4 receptor deficiency.